Mumbai, India | February 4, 2026 : Novo Medi Sciences Pvt. Ltd. (Novo Group) has announced the launch
of G.A.U.R.I. (Generating Awareness on Underprivileged Girls’ Right to
Immunization), a nationwide awareness-led vaccination mission designed
to spotlight and support the immunisation rights of underprivileged girl
children across India. At its heart, G.A.U.R.I. is built on a powerful yet
understated belief: ‘Protecting a girl child’s health should never
depend on privilege, geography, or circumstance.’ Through this campaign,
Novo Medi Sciences (Novo Group) aims to transform awareness into action,
starting with something as simple as a missed call. At the end of this
campaign, Novo Medi Sciences hopes to reach millions of Indians and will
provide vaccination to thousands of underprivileged girl children across the
nation with NEXIPOX PLUS® against the deadly chickenpox disease.
In a country as vast and diverse as India, access to
preventive healthcare is often limited not by intent but by awareness and
reach. G.A.U.R.I. addresses this gap by inviting citizens to participate in a
collective public health effort through a simple, cost-free missed call, an
action accessible across languages, regions and socio-economic backgrounds by
leaving a missed call at 9555-466-000. People across the country
are invited to lend their voices to a growing national movement, supporting Novo
Medi Sciences’ commitment to providing NEXIPOX PLUS® (chickenpox) vaccination
to thousands of underprivileged girls. Each missed call raises awareness of the
importance of timely immunization and helps turn public participation into
on-the-ground preventive care.
The missed-call awareness phase of G.A.U.R.I. (Generating
Awareness on Underprivileged Girls’ Right to Immunization) started
from 24th January 26 (National Girl Child Day) and
will continue till 30th March 26, allowing sustained
participation over several weeks. This timeline reflects the campaign’s intent
to move beyond a single-day observance and create lasting awareness. Impact and
reach will be tracked through a dedicated microsite that displays a live count
of missed calls received. Every participant will receive an acknowledgement via
a thank-you voice message and an SMS, directing them to the microsite, ensuring
transparency, and reinforcing that each individual action contributes to
real-world change.(www.gauribynovo.com)
Sharing her perspective on the campaign, Forum
Bhagat, Managing Director, Novo Medi Sciences Pvt Ltd. (Novo Group),
said, “G.A.U.R.I. reflects Novo Medi Sciences’ belief that sustainable
public health impact is built through awareness, intent, and collective
participation, often through simple, accessible actions. Expanding on the free
vaccination drive for underprivileged girls conducted last year, the initiative
is now scaling up into a nationwide mission. Its distinct strength lies in
inclusivity, enabling citizens to contribute not through financial support or
decision-making, but by amplifying awareness and facilitating access. By
bringing together thousands of small individual actions, G.A.U.R.I.
demonstrates how collective participation can create meaningful momentum and
support long-term preventive healthcare outcomes.”
While G.A.U.R.I. begins with awareness on
underprivileged girls’ right to Immunization, its impact is rooted in
responsible execution. The vaccination phase, which will follow the awareness
drive, will be supported by qualified healthcare professionals to ensure
vaccines are administered safely and ethically, in accordance with medical
guidelines. Healthcare professionals will also play a vital role in
community engagement, helping families understand the importance of
immunisation and guiding them towards appropriate care.
Commenting on the initiative, a spokesperson
from CRY (Child Rights and You), said, “‘We sincerely
appreciate Novo Medi Sciences for their commitment to empowering India's
children.”
Novo Medi Sciences Pvt. Ltd. (Novo Group), through
G.A.U.R.I., reminds the nation that a missed call is never truly ‘missed.’ It
is a quiet yet powerful act of support—simple, free, and open to every Indian.
Without spending a single rupee, anyone can become part of this meaningful
initiative and feel proud of contributing to a larger purpose. This missed call
serves as a silent signal of support for G.A.U.R.I., helping ensure that
underprivileged girls do not miss out on their right to health protection. When
thousands of such small individual actions come together, they turn into a
collective statement—one that says no girl should ever miss her chance at a
healthier future, simply because of the circumstances she was born into.
About Novo Medi Sciences (Novo Group):
Novo Medi Sciences Pvt. Ltd. (Novo Group) is a
legacy-driven pharmaceutical company with over 80 years of expertise in
developing niche biological products such as vaccines and life-saving critical
care products. Established in 1946 by the visionary Late Shri Ramesh C. Bhagat,
who introduced several life-saving vaccines for the first time in India, Novo
Medi Sciences Pvt Ltd (Novo Group) has consistently prioritised innovation and
accessibility in healthcare. Under the stewardship of the third-generation
leadership, Forum Vipul Bhagat and Karan Vipul Bhagat — the company continues
to pioneer in immunization and critical care, with a portfolio that includes
the World's only thermostable chickenpox vaccine, NEXIPOX PLUS®. Novo Medi
Sciences (Novo Group) remains at the forefront of public health advancements,
with 40 first-to-India molecules and a robust pipeline of vaccines under
clinical trials. The company expects to launch at least two vaccines each year
starting from as early as 2026 and have a complete portfolio of niche vaccines
within the next 4 years for all age groups covering diseases such as Pneumonia,
Meningitis, Cervical Cancer, Herpes Shingles, and many more. While being dominant
in the Indian vaccine segment, the company is committed to ensuring global
healthcare access, with its medicines internationally available in over 45
countries while maintaining the highest standards of quality and efficacy since
1946.